HK1205151A1 - Anti-cd26 antibodies and uses thereof cd26 - Google Patents

Anti-cd26 antibodies and uses thereof cd26

Info

Publication number
HK1205151A1
HK1205151A1 HK15105797.7A HK15105797A HK1205151A1 HK 1205151 A1 HK1205151 A1 HK 1205151A1 HK 15105797 A HK15105797 A HK 15105797A HK 1205151 A1 HK1205151 A1 HK 1205151A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
Prior art date
Application number
HK15105797.7A
Other languages
English (en)
Chinese (zh)
Inventor
Naro Antonio Francesco Di
Original Assignee
Adienne S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48092884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1205151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adienne S A filed Critical Adienne S A
Publication of HK1205151A1 publication Critical patent/HK1205151A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
HK15105797.7A 2013-02-19 2015-06-18 Anti-cd26 antibodies and uses thereof cd26 HK1205151A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13425029.9A EP2767549A1 (en) 2013-02-19 2013-02-19 Anti-CD26 antibodies and uses thereof
PCT/EP2014/053243 WO2014128168A1 (en) 2013-02-19 2014-02-19 Anti-cd26 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HK1205151A1 true HK1205151A1 (en) 2015-12-11

Family

ID=48092884

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105797.7A HK1205151A1 (en) 2013-02-19 2015-06-18 Anti-cd26 antibodies and uses thereof cd26

Country Status (26)

Country Link
US (2) US9376498B2 (hr)
EP (3) EP2767549A1 (hr)
JP (2) JP6240195B2 (hr)
KR (1) KR101869589B1 (hr)
CN (1) CN104684931B (hr)
AU (1) AU2014220777B2 (hr)
CA (1) CA2874422C (hr)
CY (1) CY1121980T1 (hr)
DK (1) DK2864359T3 (hr)
ES (1) ES2738283T3 (hr)
HK (1) HK1205151A1 (hr)
HR (1) HRP20191277T8 (hr)
HU (1) HUE045150T2 (hr)
IL (1) IL237244B (hr)
LT (1) LT2864359T (hr)
ME (1) ME03753B (hr)
MX (1) MX357293B (hr)
NZ (1) NZ631111A (hr)
PL (1) PL2864359T3 (hr)
PT (1) PT2864359T (hr)
RS (1) RS59093B1 (hr)
RU (1) RU2662933C2 (hr)
SA (1) SA515360248B1 (hr)
SI (1) SI2864359T1 (hr)
TR (1) TR201910572T4 (hr)
WO (1) WO2014128168A1 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11242399B2 (en) * 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US10630229B2 (en) * 2016-10-11 2020-04-21 Kevin Stapleton Panel mounting bracket with grounding mid-clamp and related methods
KR101960414B1 (ko) * 2016-11-11 2019-03-27 대한민국 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도
MA51309A (fr) 2017-12-22 2021-03-31 Adienne S A Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
US20230295328A1 (en) * 2020-07-28 2023-09-21 Adienne S.A. Treatment of idiopathic inflammatory myopathies
BR112023022312A2 (pt) * 2021-05-13 2023-12-26 Adienne S A Métodos de tratamento de dermatomiosite
JP2024517337A (ja) * 2021-05-13 2024-04-19 アディエンネ・ソチエタ・アノニマ 移植片対宿主病を処置する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
NL9400309A (nl) * 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
ATE335005T1 (de) 1998-04-15 2006-08-15 Genentech Inc Menschliches protein mit in vitro antiproliferativer aktivität.
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
JP2004533449A (ja) * 2001-05-11 2004-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
BRPI0607486B8 (pt) 2005-03-03 2021-05-25 Immunomedics Inc anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
CA2615615A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co., Ltd. Anti-cd26 antibodies and methods of use thereof
US20070060528A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
RU2331881C1 (ru) * 2007-03-09 2008-08-20 ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ определения риска развития атопических заболеваний у новорожденных детей
JP5792621B2 (ja) 2008-09-26 2015-10-14 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
AU2011291651B2 (en) * 2010-08-18 2016-01-14 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof

Also Published As

Publication number Publication date
HRP20191277T1 (hr) 2019-10-18
IL237244B (en) 2019-09-26
KR101869589B1 (ko) 2018-06-20
EP2767549A1 (en) 2014-08-20
SI2864359T1 (sl) 2019-09-30
ES2738283T3 (es) 2020-01-21
WO2014128168A1 (en) 2014-08-28
TR201910572T4 (tr) 2019-08-21
EP2864359A1 (en) 2015-04-29
BR112015002130A2 (pt) 2017-11-07
HRP20191277T8 (hr) 2019-11-01
CY1121980T1 (el) 2020-10-14
RS59093B1 (sr) 2019-09-30
CA2874422A1 (en) 2014-08-28
IL237244A0 (en) 2015-04-30
DK2864359T3 (da) 2019-07-22
SA515360248B1 (ar) 2017-02-20
PL2864359T3 (pl) 2019-11-29
ME03753B (me) 2021-04-20
RU2662933C2 (ru) 2018-07-31
JP6240195B2 (ja) 2017-11-29
PT2864359T (pt) 2019-07-26
CN104684931A (zh) 2015-06-03
JP2015529204A (ja) 2015-10-05
CN104684931B (zh) 2019-08-27
LT2864359T (lt) 2019-09-25
HUE045150T2 (hu) 2019-12-30
US20160264676A1 (en) 2016-09-15
EP3536711A1 (en) 2019-09-11
AU2014220777B2 (en) 2017-03-16
MX357293B (es) 2018-07-04
US10208126B2 (en) 2019-02-19
MX2014014935A (es) 2015-06-17
KR20150023419A (ko) 2015-03-05
US20150017178A1 (en) 2015-01-15
US9376498B2 (en) 2016-06-28
CA2874422C (en) 2021-10-19
JP2017221205A (ja) 2017-12-21
EP2864359B1 (en) 2019-04-24
AU2014220777A1 (en) 2014-11-27
NZ631111A (en) 2017-06-30
RU2014153440A (ru) 2016-07-20

Similar Documents

Publication Publication Date Title
IL261743B (en) and their uses 33–il antibodies against
IL261547B (en) Antibodies against pesidine and their uses
IL245040B (en) Antibodies against pdgfr-beta and their uses
HK1225322A1 (zh) 抗激活蛋白a抗體及其用途
IL243974B (en) Antibodies against –prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
IL240517A0 (en) Antibodies against b7–h4 and immunoconjugates
SG10201709715RA (en) Anti-b7-h5 antibodies and their uses
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
EP2953970A4 (en) TRANSTYRETIN ANTIBODIES AND USES THEREOF
HRP20191277T8 (hr) Anti-cd26 antitijela i njihove primjene